Prelude Therapeutics Incorporated (PRLD)
NASDAQ
Closed
Oct 8, 2026
Day's Range
3.6652 wk Range
1.15Overview - PRLD - Prelude Therapeutics Incorporated
Key Statistics
Valuation
Enterprise Value
243.88M
P/E (Trailing)
‪-2.84‬
P/E (Forward)
‪-6.67‬
PEG Ratio
‪0.04‬
Price / Sales (TTM)
‪13.03‬
Price / Book
‪2.82‬
EV / EBITDA
‪-3.78‬
Profitability
Profit Margin
‪-269.74%‬
Operating Margin
‪-270.93%‬
Return on Assets
‪-27.15%‬
Return on Equity
‪-57.72%‬
Ownership
Shares Outstanding
79.75M
Float
22.06M
Short % of Shares Outstanding
‪14.33%‬
Held by Insiders
‪13.76%‬
Held by Institutions
‪76.44%‬
Price stats
Beta
‪0.96‬
50-Day Avg
‪4.98‬
200-Day Avg
‪3.88‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
5 analysts
Average price target
‪$ 8.00‬Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - PRLD - Prelude Therapeutics Incorporated
Peers - PRLD - Prelude Therapeutics Incorporated
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- PRLDNASDAQPrelude Therapeutics Incorporated292.29MMarket Cap+60.22%52-week change-2.84P/E (Trailing)‪-269.74%‬Profit Margin
- ARGXNASDAQArgenx SE57.50BMarket Cap+14.28%52-week change34.96P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.40BMarket Cap-105.72%52-week change38.35P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share24.34BMarket Cap-8.52%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.99BMarket Cap+7.48%52-week change17.72P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.14BMarket Cap+18.80%52-week change-17.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.11.06BMarket Cap+2.75%52-week change154.54P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - PRLD - Prelude Therapeutics Incorporated
About
Prelude Therapeutics Incorporated is a clinical-stage precision oncology company focused on discovering and developing novel medicines for cancer patients with high unmet medical needs. Prelude Therapeutics Incorporated is advancing a pipeline of targeted therapies designed to address genetically defined cancers and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
